… of Evolocumab in Chinese Patients with Primary Hypercholesterolemia and Mixed Dyslipidemia: 12-Week Primary Results of the HUA TUO 华佗Randomized Clinical …
H Tan, W Li, Z Huang, Y Han, X Huang, D Li… - Cardiology and …, 2023 - Springer
… study evaluated the efficacy and safety of evolocumab in Chinese patients with primary
hypercholesterolemia and mixed dyslipidemia at different levels of cardiovascular disease risk. …
hypercholesterolemia and mixed dyslipidemia at different levels of cardiovascular disease risk. …
PCSK9 抑制剂相关研究进展
月环杨， 璐莎鄂 - 亚洲临床医学杂志, 2023 - ojs.sp.sg
… Association between lowering LDL-C and cardiovascular risk reduction among different …
Evolocumab and clinical outcomes in patients with card iovascular disease[J]. N Engl J Med,…
Evolocumab and clinical outcomes in patients with card iovascular disease[J]. N Engl J Med,…
[HTML][HTML] 动脉粥样硬化性心血管疾病高危人群胆固醇管理的临床研究进展
孙冰， 王海昌 - 南京医科大学学报(自然科学版), 2021 - jnmu.njmu.edu.cn
… Evolocumab and clinical outcomes in patients with cardio⁃ vascular disease[J].N Engl J …
Control of cholesterol levels can reduces the incidence of atherosclerotic cardiovascular disease…
Control of cholesterol levels can reduces the incidence of atherosclerotic cardiovascular disease…
[HTML][HTML] 心血管疾病领域全球研究热点——基于ESI 热点论文的计量分析
子晴席， 小清龚， 柏宏李， 龙浩张， 剑蒲… - Sheng Wu Yi Xue …, 2020 - ncbi.nlm.nih.gov
… 依尤洛单抗 · Evolocumab and clinical outcomes in patients with cardiovascular disease [11]
544 N Engl J Med · Effect of evolocumab on progression of coronary disease in statin-…
544 N Engl J Med · Effect of evolocumab on progression of coronary disease in statin-…
[PDF][PDF] PCSK9 抑制剂对极高危动脉粥样硬化性心血管疾病患者血脂谱的影响
王晶， 邓松柏， 刘亚杰， 佘强， 杜建霖 - 中华危重病急救医学, 2020 - cccm-em120.com
… Evolocumab and clinical outcomes in patients with cardiovascular disease [J]. N Engl J Med…
Efficacy and safety of evolocumab in reducing lipids and cardiovascular events [J]. N Engl J …
Efficacy and safety of evolocumab in reducing lipids and cardiovascular events [J]. N Engl J …
[PDF][PDF] 阿托伐他汀联合依洛尤单抗治疗极高风险动脉粥样硬化心血管疾病患者效果的研究
郝敬严 - 中国医学创新 - zgyxcx.com
… Evolocumab and clinical outcomes in patients with cardiovascular disease[J].N Engl J
Med,2017,376(18):1713-1722. [7] BHATT DL,… Evolocumab and clinical outcomes in patients with …
Med,2017,376(18):1713-1722. [7] BHATT DL,… Evolocumab and clinical outcomes in patients with …
≤ 45 岁急性冠脉综合征患者中超高危冠状动脉粥样硬化性心脏病人群降脂治疗后血脂达标率及影响因素研究
高扬， 王贇霞， 张优， 高传玉 - 中国全科医学, 2023 - chinagp.net
… The associations of muscle strength,muscle mass,and adiposity with clinical outcomes and
quality … Evolocumab and clinical outcomes in patients with cardiovascular disease[J]. JR Coll …
quality … Evolocumab and clinical outcomes in patients with cardiovascular disease[J]. JR Coll …
[HTML][HTML] 降脂药物对认知功能影响的综述与前瞻
韩立君， 苏畅， 高聆 - Advances in Clinical Medicine, 2024 - hanspub.org
… Future research should focus on long-term effects and underlying mechanisms to provide
comprehensive health management strategies for patients with cardiovascular diseases. …
comprehensive health management strategies for patients with cardiovascular diseases. …
PCSK9 抑制剂在脂代谢中的研究进展
刘壮， 耿雪梅， 柯永胜 - 大连医科大学学报, 2019 - journal.dmu.edu.cn
: 前蛋白转换酶枯草溶菌素9 (PCSK9) 是参与调节低密度脂蛋白受体(LDLR) 表达, 通过促进溶酶
体对LDLR 的消化作用降低了细胞表面LDLR 的密度, 进而导致血浆低密度脂蛋白胆固醇(LDL-C…
体对LDLR 的消化作用降低了细胞表面LDLR 的密度, 进而导致血浆低密度脂蛋白胆固醇(LDL-C…
[HTML][HTML] PCSK9 单克隆抗体: 12 年, 从基础研究到临床应用
应航鹰， 王嘉程， 周斌全 - Advances in Clinical Medicine, 2019 - hanspub.org
… risk factors for ischemic cardiovascular diseases, PCSK9 inhibitors rapidly become a new
hotspot of blood lipid management. Antibodies applied clinically are Alirocumab, Evolocumab …
hotspot of blood lipid management. Antibodies applied clinically are Alirocumab, Evolocumab …